Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Boehringer Ingelheim
Merck
Harvard Business School
Baxter

Last Updated: December 13, 2019

DrugPatentWatch Database Preview

Litigation Details for Cadence Pharmaceuticals Inc. v. Exela Pharma Sciences LLC (D. Del. 2011)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Cadence Pharmaceuticals Inc. v. Exela Pharma Sciences LLC (D. Del. 2011)

Docket   Start Trial Date Filed 2011-08-18
Court District Court, D. Delaware Date Terminated 2013-11-22
Cause 35:271 Patent Infringement Assigned To Leonard Philip Stark
Jury Demand None Referred To
Parties CADENCE PHARMACEUTICALS INC.; EXELA HOLDINGS INC.; EXELA PHARMA SCIENCES LLC; EXELA PHARMSCI INC.; PADDOCK LABORATORIES INC.; PADDOCK LABORATORIES LLC; PERRIGO COMPANY; SCR PHARMATOP
Patents 6,028,222; 6,992,218
Attorneys Adam Wyatt Poff; Jack B. Blumenfeld; Richard L. Horwitz; Robert J. Katzenstein; Thomas C. Grimm
Link to Docket External link to docket
Small Molecule Drugs cited in Cadence Pharmaceuticals Inc. v. Exela Pharma Sciences LLC
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Cadence Pharmaceuticals Inc. v. Exela Pharma Sciences LLC (D. Del. 2011)

Date Filed Document No. Description Snippet Link To Document
2012-10-04 231 infringement of U.S. Patent Nos. 6,028,222 (the ’222 patent) and 6,992,218 (the ’21 8 patent) under 35 U.S.C…rights in the patents-in-suit. Plaintiff SCR Pharmatop, the patent owner, licensed the patents to BMS. BMS…sublicensed the patents to plaintiff Cadence but BMS retained substantial rights in the patents _ Th@r€f@r@… “ALL SUBSTANTIAL RIGHTS” IN THE PATENTS Standing to bring a patent suit is a question of subject matter… of the patent, such that the exclusive licensee holds “all substantial rights” in the patent. Alfr" External link to document
2012-10-24 249 8. The term “the Patents~in-Suit” means U.S. Patent No. 6,028,222 and U.S. Patent No. 6,992,218, collectively…Paddook”);_ WHEREAS, Plaintiffs suedPaddocl< for patent infringement based on Paddock’s filing of ANDA…concerning the use of any information set forth in the Patents- in-Suit during the development of the Paddock … 22 November 2013 1:11-cv-00733 830 Patent None District Court, D. Delaware External link to document
2012-11-09 268 and ‘218 patents Plaintiffs seek to obtain evidence relating to U.S. Patent Nos. 6,028,222 and 6,992,218… Defendants infringe the claims of U.S. Patent Nos. 6,028,222 and 6,992,218 based upon Case 1:11-CV-OO733…defenses offered are that the claims ofU.S. Patent Nos. 6,028,222 and 6,992,218 are invalid or would not be… and information pertinent to the issues in the patent litigation in the District Court for the District…Which the evidence is requested concerns a civil patent infringement lawsuit based upon a complaint filed External link to document
2012-12-07 284 claims ofU.S. Patent Nos. 6,028,222 and 6,992,… claims of U.S. Patent Nos. 6,028,222 … relating to U.S. Patent Nos. 6,028,222 … in the patent litigation in the District …etc.): concerns a civil patent infringement External link to document
2012-12-21 291 Exhibit A-C of U.S. Patent No. 6,028,222, and that, as a result of such reexamination, claims in that patent may be… patents that cover OFIRMEV, a formulation patent that expires in 2018 and a process patent that …The United States Patent and Trademark Office specifically considered the ’222 Patent as a prior art reference… determined that the claims of the ’218 Patent were patentable over it. Accordingly, Exela’s burden …the ’222 Patent standing alone. Cadence states that claims 3, 4, 8, 9 and 19 of the ’218 Patent are not External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Johnson and Johnson
McKinsey
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.